Research Analysts’ Recent Ratings Updates for Evolent Health (EVH)
by Michael Walen · The Markets DailyEvolent Health (NYSE: EVH) has recently received a number of price target changes and ratings updates:
- 8/18/2026 – Evolent Health was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
- 8/18/2026 – Evolent Health had its price target raised by JPMorgan Chase & Co. from $5.00 to $6.00. They now have an “overweight” rating on the stock.
- 8/17/2026 – Evolent Health had its price target raised by TD Cowen from $5.00 to $6.00. They now have a “buy” rating on the stock.
- 8/12/2026 – Evolent Health had its price target lowered by Truist Financial Corporation from $7.00 to $6.00. They now have a “hold” rating on the stock.
- 8/10/2026 – Evolent Health was upgraded by Citigroup Inc. from “neutral” to “buy”. They now have a $6.00 price target on the stock, down from $6.75.
- 8/10/2026 – Evolent Health had its price target lowered by Canaccord Genuity Group Inc. from $7.00 to $6.00. They now have a “buy” rating on the stock.
- 8/4/2026 – Evolent Health was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
- 7/28/2026 – Evolent Health had its price target lowered by TD Cowen from $8.00 to $5.00. They now have a “buy” rating on the stock.
- 7/23/2026 – Evolent Health had its “sell” rating reaffirmed by Citigroup Inc.. They now have a $6.75 price target on the stock, up from $5.50.
- 7/23/2026 – Evolent Health had its “sell” rating reaffirmed by Citigroup Inc.. They now have a $6.75 price target on the stock, up from $5.50.
- 7/21/2026 – Evolent Health was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
- 7/21/2026 – Evolent Health had its price target raised by Canaccord Genuity Group Inc. from $6.00 to $7.00. They now have a “buy” rating on the stock.
- 7/8/2026 – Evolent Health was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
- 6/30/2026 – Evolent Health was downgraded by Truist Financial Corporation from “buy” to “hold”. They now have a $7.00 price target on the stock.
Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.
The company’s core offerings include care management solutions, population health analytics and clinical advisory services.